A Phase 2 interventional study of MBX-8025 2 mg Capsule and MBX-8025 5 mg Capsule in Primary Biliary Cirrhosis, sponsored by Gilead Sciences. Completed at 38 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-07-14.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences — 2 open to participants now, 3 under way, 2 of them phase 3. Liver Cirrhosis, Biliary · Gilead Sciences.
Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, this one is the 6th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 3rd registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →2 of the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences are open now, in 12 countries. Recruiting first, the newest first:
Gilead Sciences · Sites in United States
Ages 18–75
Gilead Sciences · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 126 across the 10 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)
Primary:
To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 8 weeks of treatment
Secondary:
To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 12 and 26 weeks of treatment
To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 52 weeks of treatment
To evaluate the pharmacokinetics (PK) of MBX-8025
Exploratory:
To evaluate the effect of MBX-8025 on bile acids, additional markers of inflammation and renal function
MBX-8025 doses of 1 mg and 15 mg may be evaluated if dose adjustment occurs
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female with a diagnosis of PBC, by at least two of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MBX-8025 2 mg capsule once daily
Drug: MBX-8025 2 mg Capsule
MBX-8025 5 mg capsule once daily
Drug: MBX-8025 5 mg Capsule
MBX-8025 10 mg capsule once daily
Drug: MBX-8025 10 mg Capsule
Initial 8-week treatment: • MBX-8025 2 mg Extension: The 2 mg group will be started after safety and efficacy review of the 5 mg and the 10 mg groups has been completed. Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.
Also known as: MBX-8025, seladelpar
Initial 8-week treatment: • MBX-8025 5 mg Extension: Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.
Also known as: MBX-8025, seladelpar
Initial 8-week treatment: • MBX-8025 10 mg Extension: Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.
Also known as: MBX-8025, seladelpar
Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 8
Relative change from baseline in serum ALP levels at Week 8 (endpoint). The modified Intent-to-Treat (mITT) analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment. n, denotes number of subjects evaluable for the respective timepoints
Time frame: 8 weeks
Absolute Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 12 and Week 52
Absolute change in ALP from baseline to Weeks 12 and 52 The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
Time frame: 12 weeks and 52 weeks
Change in Aspartate Aminotransferase (AST) From Baseline to 12 Weeks and 52 Weeks
Change from baseline in AST levels at endpoint was reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
Time frame: 12 weeks and 52 weeks
Change in Alanine Aminotransferase (ALT) From Baseline to 12 Weeks and 52 Weeks
Change from baseline in ALT levels at endpoint was reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
Time frame: 12 weeks and 52 weeks
Change in Gamma-glutamyl Transferase (GGT) From Baseline to 12 Weeks and 52 Weeks
Change from baseline in GGT levels at endpoint was reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
Time frame: 12 weeks and 52 weeks
Change in Bilirubin - Total Bilirubin (TB) From Baseline to 12 Weeks and 52 Weeks
Change from baseline in TB levels at endpoint is being reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
Time frame: 12 weeks and 52 weeks
Percentage of Participants Meet Composite Endpoint Criteria of ALP and Total Bilirubin
Participant meets composite endpoint is defined by participant meets all of the following criteria: * ALP \< 1.67 × upper limit of normal (ULN) * Total Bilirubin within normal limit * \> 15% decrease in ALP Endpoint of Alkaline Phosphatase and Total Bilirubin by Visit (mITT Population)
Time frame: 12 Weeks and 52 Weeks
Percentage of Participants Meet Published PBC Response Criteria - Paris I
Percentage of participants with response based on Paris I risk score was defined as ALP less than or equal to (≤) 3x ULN and aspartate aminotransferase (AST) less than or equal to (≤) 2 x ULN and Total Bilirubin ≤ 1 mg/dL. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
Time frame: 12 weeks and 52 weeks
Percentage of Participants Meet Published PBC Response Criteria - Paris II
Percentage of participants with response based on Paris II risk score was defined as ALP≤1.5xULN and AST≤1.5xULN and Total Bilirubin ≤ 1 mg/dL. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
Time frame: 12 weeks and 52 weeks
Percentage of Participants Meet Published PBC Response Criteria - Toronto I
Percentage of participants with response based on Toronto I risk score defined as ALP ≤ 1.67 x ULN. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
Time frame: 12 weeks and 52 weeks
UK-PBC Risk Score Value
The UK-PBC Risk Score at endpoint is defined by the mean percentage risk that a PBC patient treated with ursodeoxycholic acid (UDCA) would develop liver failure requiring liver transplantation in 5, 10 and 15 years from diagnosis. The higher the score might indicate higher risk to death or live transplantation. Formula used for UK-PBC risk score = 1- 0.982 \^EXP(0.0287854\*(ALP12 x ULN-1.722136304) - 0.0422873\*(((TA12 xULN/10)\^-1) - 8.675729006) + 1.4199 \* (LN(BIL12 x ULN/10)+2.709607778)-1.960303\*(Albumin x LLN-1.17673001)-0.4161954\*(Platelet x LLN-1.873564875)). Where, Baseline survivor function = 0.982, 0.941, and 0.893 for 5 years, 10 years and 15 years respectively. ALP12, TA12 and BIL12 refers to the ALP, transaminases (ALT, AST), and total bilirubin assessments, respectively. The modified Intent-to-Treat (mITT) analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
Time frame: 12 weeks and 52 weeks
Change From Baseline in Pruritus Visual Analog Score (VAS) at Week 12 and Week 52
VAS is the commonly used graphic tool for self-reporting of pruritus intensity in patients. VAS is a simple to use, validated, reliable and widely applicable tool that does not determine the impact of pruritus to quality of life. It comprises of a 100-mm horizontal line labelled as "no symptom" on left end and "worst imaginable symptom" on right end. Based on the intensity of the itch patient is instructed to draw a vertical line on the horizontal scale having a range \[VAS values (unit: mm) ranging from 0 to 100, where 0 represents "no itching" and 100 "worst possible itching"\]. The modified Intent-to-Treat (mITT) analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
Time frame: 12 weeks and 52 weeks
Change From Baseline in PBC-40 Quality of Life (QoL) at Week 12 and Week 52
The PBC-40 QoL questionnaire is a disease-specific health-related tool developed for measuring the psychometric profile in PBC patients. It has 10 domains and 43 questions relevant to PBC, including Cognitive, Social, Emotional Function, Fatigue, Itch, and Other Symptoms. Questions in domains: 1) digestion and diet (questions 1-3); 2) experiences (questions 4-7); 3) itching (questions 8-10); 4) fatigue (questions 11-18); 5) effort and planning (questions 19-21); 6) memory and concentration (questions 22-27); 7) affects to you as person (questions 28-33); 8) affects to your social life (questions 34-37); 9) overall impact on your life (questions 38-40); 10) general health and well-being (questions A-C). Within a domain, items are scored from 1 to 5 and the individual item scores are summed to give a total domain score. High scores represent high impact and low scores low impact of PBC on QoL (mITT Population).
Time frame: 12 weeks and 52 weeks
Percentage of Participants Meet Published PBC Response Criteria - Barcelona
Percentage of participants with response based on Barcelona risk scores was defined as Normalization of ALP or a Decrease of ALP ≥ 40%. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
Time frame: 12 weeks and 52 weeks
Absolute Change in MELD Score From Baseline to 12 Weeks and 52 Weeks
Change from baseline to 12 weeks and 52 weeks in Model for End-stage Liver Disease (MELD) Score (mITT Population) The MELD score ranges from 6 to 40 and is a measure of how severe a patient's liver disease is. The higher the score, the more likely the patients will need a liver transplant. A calculated prognostic risk factor used to assess the potential need for a liver transplant. MELD(i) score = 10\*\[0.957\*ln(creatinine mg/dL) + 0. 378\*ln(total bilirubin mg/dL) + 1.120\*ln (INR) + 0.643\]. If MELD(i) is less than or equal to 11 then MELD = MELD(i). If MELD(i) is greater than 11 then MELD = MELD(i) + (1.32 \*(137 - (Na)) - (0.033\*MELD(i)\*(137 - Na))
Time frame: 12 weeks and 52 weeks
Change in GLOBE PBC Score From Baseline to 12 Weeks and 52 Weeks
Change from Baseline to 12 weeks and 52 weeks in Global PBC Study Group (GLOBE) score (mITT Population) The GLOBE score is a validated risk assessment tool providing an estimate of transplant-free survival for patients with PBC. It was developed by the Global PBC Study Group using Cox regression model on over 4,000 patients with PBC. Lower GLOBE score predicts lower risk. It is calculated from the following equation: GLOBE score = (0.044378 \* age + 0.93982 \* LN(total bilirubin/ULN) +(0.335648 \* LN(alkaline phosphatase/ULN)) - 2.266708 \* albumin /LLN -0.002581 \* platelet count per 109/L) + 1.216865
Time frame: 12 weeks and 52 weeks
Participants Meet Rotterdam Criteria
participants with Response Based on Rotterdam Criteria at Weeks 12 and 52 Rotterdam Published PBC Response Criteria by Visit (mITT Population) Rotterdam criteria: Early (normal total bilirubin and normal albumin), Moderately advanced (either abnormal albumin or abnormal total bilirubin), and Advanced (both abnormal albumin and abnormal total bilirubin). From Early stage to Moderate Stage and to Advanced Stage, it becomes worse and worse in abnormality.
Time frame: 12 weeks and 52 weeks
Percentage of Participants Meet Composite Endpoint of AP and Total Bilirubin Criteria at Week 12 and Week 52
Percentage of participants with Response Defined by Composite Endpoint (ALP\< 1.67 \* Upper Limit of Normal \[ULN\] at Endpoint, Total Bilirubin \[BIL\] within Normal Limits at Endpoint, and Greater Than Equal To \[≥\] 15% ALP Reduction) from Baseline to Week 12 and Week 52 The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
Time frame: 12 weeks and 52 weeks
Percent Change in Serum Alkaline Phosphatase (ALP)
Percent change in ALP from baseline to Weeks 12 and 52 The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
Time frame: 12 weeks and 52 weeks
| Milestone | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Started | 11 | 53 | 55 |
| Completed | 10 | 46 | 49 |
| Not completed | 1 | 7 | 6 |
| Withdrew: Adverse event | 0 | 3 | 0 |
| Withdrew: Withdrawal of informed consent | 1 | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Other | 0 | 1 | 3 |
Relative change from baseline in serum ALP levels at Week 8 (endpoint). The modified Intent-to-Treat (mITT) analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment. n, denotes number of subjects evaluable for the respective timepoints
| percentage change from baseline | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 8 | -26.06 ± 9.15 | -33.38 ± 17.81 | -41.42 ± 13.05 |
Absolute change in ALP from baseline to Weeks 12 and 52 The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
| U/L | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Absolute Change at Week 12 | -68.318 ± 63.276 | -135.902 ± 150.954 | -127.867 ± 60.284 |
| Absolute Change at Week 52 | -101.150 ± 107.956 | -158.310 ± 143.668 | -133.760 ± 76.151 |
Change from baseline in AST levels at endpoint was reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
| U/L | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Week 12 | -2.50 ± 16.72 | -1.13 ± 24.28 | -3.35 ± 10.55 |
| Week 52 | -7.05 ± 10.50 | -6.18 ± 13.98 | -6.14 ± 9.18 |
Change from baseline in ALT levels at endpoint was reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
| U/L | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Week 12 | -5.59 ± 16.07 | -10.48 ± 21.41 | -10.87 ± 20.25 |
| Week 52 | -14.30 ± 25.12 | -17.29 ± 17.46 | -15.32 ± 13.89 |
Change from baseline in GGT levels at endpoint was reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
| U/L | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Week 12 | -43.68 ± 56.87 | -75.35 ± 87.57 | -80.82 ± 109.06 |
| Week 52 | -78.60 ± 81.59 | -91.37 ± 102.23 | -88.08 ± 122.14 |
Change from baseline in TB levels at endpoint is being reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
| mg/dL | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Week 12 | -0.010 ± 0.121 | -0.055 ± 0.161 | -0.067 ± 0.199 |
| Week 52 | 0.002 ± 0.152 | -0.028 ± 0.263 | -0.068 ± 0.190 |
Participant meets composite endpoint is defined by participant meets all of the following criteria: * ALP \< 1.67 × upper limit of normal (ULN) * Total Bilirubin within normal limit * \> 15% decrease in ALP Endpoint of Alkaline Phosphatase and Total Bilirubin by Visit (mITT Population)
| percentage of participants | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Week 12 | 45.5 | 48.9 | 66.7 |
| Week 52 | 63.6 | 53.3 | 67.3 |
Percentage of participants with response based on Paris I risk score was defined as ALP less than or equal to (≤) 3x ULN and aspartate aminotransferase (AST) less than or equal to (≤) 2 x ULN and Total Bilirubin ≤ 1 mg/dL. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
| percentage of participants | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Week 12 | 81.8 | 76.1 | 75.5 |
| Week 52 | 90 | 81.0 | 79.2 |
Percentage of participants with response based on Paris II risk score was defined as ALP≤1.5xULN and AST≤1.5xULN and Total Bilirubin ≤ 1 mg/dL. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
| percentage of participants | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Week 12 | 36.4 | 37.0 | 59.2 |
| Week 52 | 50.0 | 54.8 | 60.4 |
Percentage of participants with response based on Toronto I risk score defined as ALP ≤ 1.67 x ULN. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
| percentage of subjects | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Week 12 | 63.6 | 51.1 | 78.4 |
| Week 52 | 63.6 | 57.8 | 71.4 |
The UK-PBC Risk Score at endpoint is defined by the mean percentage risk that a PBC patient treated with ursodeoxycholic acid (UDCA) would develop liver failure requiring liver transplantation in 5, 10 and 15 years from diagnosis. The higher the score might indicate higher risk to death or live transplantation. Formula used for UK-PBC risk score = 1- 0.982 \^EXP(0.0287854\*(ALP12 x ULN-1.722136304) - 0.0422873\*(((TA12 xULN/10)\^-1) - 8.675729006) + 1.4199 \* (LN(BIL12 x ULN/10)+2.709607778)-1.960303\*(Albumin x LLN-1.17673001)-0.4161954\*(Platelet x LLN-1.873564875)). Where, Baseline survivor function = 0.982, 0.941, and 0.893 for 5 years, 10 years and 15 years respectively. ALP12, TA12 and BIL12 refers to the ALP, transaminases (ALT, AST), and total bilirubin assessments, respectively. The modified Intent-to-Treat (mITT) analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
| units on a scale | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| 5 years, week 12 | 1.3929 ± 0.6976 | 2.2553 ± 2.5145 | 1.8124 ± 1.7267 |
| 5 years, week 52 | 1.3145 ± 0.7704 | 2.3485 ± 3.432 | 1.7244 ± 1.6121 |
| 10 years week 12 | 4.5705 ± 2.2479 | 7.1229 ± 7.4904 | 5.8293 ± 5.3605 |
| 10 years, week 52 | 4.3128 ± 2.4649 | 7.2322 ± 9.5794 | 5.5607 ± 5.0092 |
| 15 years, week 12 | 8.3008 ± 3.9932 | 12.4002 ± 12.1785 | 10.3469 ± 9.1269 |
| 15 years, week 52 | 7.8325 ± 4.3413 | 12.3028 ± 14.5701 | 9.9008 ± 8.5396 |
VAS is the commonly used graphic tool for self-reporting of pruritus intensity in patients. VAS is a simple to use, validated, reliable and widely applicable tool that does not determine the impact of pruritus to quality of life. It comprises of a 100-mm horizontal line labelled as "no symptom" on left end and "worst imaginable symptom" on right end. Based on the intensity of the itch patient is instructed to draw a vertical line on the horizontal scale having a range \[VAS values (unit: mm) ranging from 0 to 100, where 0 represents "no itching" and 100 "worst possible itching"\]. The modified Intent-to-Treat (mITT) analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
| score on a scale | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Week 12 | -3.7 ± 6.4 | -5.5 ± 25.0 | -12.3 ± 22.3 |
| Week 52 | -3.3 ± 11.7 | -9.6 ± 22.5 | -16.5 ± 23.0 |
The PBC-40 QoL questionnaire is a disease-specific health-related tool developed for measuring the psychometric profile in PBC patients. It has 10 domains and 43 questions relevant to PBC, including Cognitive, Social, Emotional Function, Fatigue, Itch, and Other Symptoms. Questions in domains: 1) digestion and diet (questions 1-3); 2) experiences (questions 4-7); 3) itching (questions 8-10); 4) fatigue (questions 11-18); 5) effort and planning (questions 19-21); 6) memory and concentration (questions 22-27); 7) affects to you as person (questions 28-33); 8) affects to your social life (questions 34-37); 9) overall impact on your life (questions 38-40); 10) general health and well-being (questions A-C). Within a domain, items are scored from 1 to 5 and the individual item scores are summed to give a total domain score. High scores represent high impact and low scores low impact of PBC on QoL (mITT Population).
| units on a scale | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| General Symptoms, Week 12 | 1.9 ± 2.7 | -0.7 ± 5.1 | -0.5 ± 3.6 |
| General Symptoms, Week 52 | 0.3 ± 2.4 | -1.4 ± 4.4 | -0.1 ± 4.4 |
| Itch, Week 12 | -0.4 ± 2.0 | -0.5 ± 3.4 | -0.8 ± 3.1 |
| Itch, Week 52 | 0.4 ± 2.7 | -1.3 ± 3.2 | -1.4 ± 3.7 |
| Fatigue, Week 12 | -1.5 ± 6.1 | -2.1 ± 10.4 | -3.0 ± 5.2 |
| Fatigue, Week 52 | -1.2 ± 7.8 | -3.0 ± 8.5 | -3.4 ± 6.3 |
| Cognitive Function, Week 12 | -0.9 ± 2.4 | -0.6 ± 5.7 | -0.7 ± 2.8 |
| Cognitive Function, Week 52 | -0.7 ± 7.6 | -1.4 ± 5.3 | -0.6 ± 2.5 |
| Social, Week 12 | 0.8 ± 2.8 | -0.5 ± 7.9 | -1.0 ± 6.3 |
| Social, Week 52 | -3.3 ± 5.2 | -1.6 ± 7.2 | -1.6 ± 6.2 |
| Emotional, Week 12 | -0.9 ± 1.6 | -1.0 ± 2.6 | -0.8 ± 2.1 |
| Emotional, Week 52 | -2.1 ± 2.3 | -1.3 ± 2.7 | -0.9 ± 2.1 |
Percentage of participants with response based on Barcelona risk scores was defined as Normalization of ALP or a Decrease of ALP ≥ 40%. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
| percentage of participants | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Week 12 | 9.1 | 42.6 | 62.7 |
| Week 52 | 45.5 | 66.7 | 65.3 |
Change from baseline to 12 weeks and 52 weeks in Model for End-stage Liver Disease (MELD) Score (mITT Population) The MELD score ranges from 6 to 40 and is a measure of how severe a patient's liver disease is. The higher the score, the more likely the patients will need a liver transplant. A calculated prognostic risk factor used to assess the potential need for a liver transplant. MELD(i) score = 10\*\[0.957\*ln(creatinine mg/dL) + 0. 378\*ln(total bilirubin mg/dL) + 1.120\*ln (INR) + 0.643\]. If MELD(i) is less than or equal to 11 then MELD = MELD(i). If MELD(i) is greater than 11 then MELD = MELD(i) + (1.32 \*(137 - (Na)) - (0.033\*MELD(i)\*(137 - Na))
| Change from Baseline | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Week 12 | -0.3 ± 1.6 | 0.1 ± 1.2 | 0.1 ± 1.0 |
| Week 52 | -0.7 ± 1.6 | 0.3 ± 1.1 | 0.2 ± 1.2 |
Change from Baseline to 12 weeks and 52 weeks in Global PBC Study Group (GLOBE) score (mITT Population) The GLOBE score is a validated risk assessment tool providing an estimate of transplant-free survival for patients with PBC. It was developed by the Global PBC Study Group using Cox regression model on over 4,000 patients with PBC. Lower GLOBE score predicts lower risk. It is calculated from the following equation: GLOBE score = (0.044378 \* age + 0.93982 \* LN(total bilirubin/ULN) +(0.335648 \* LN(alkaline phosphatase/ULN)) - 2.266708 \* albumin /LLN -0.002581 \* platelet count per 109/L) + 1.216865
| units on a scale | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Week 12 | -0.079 ± 0.260 | -0.292 ± 0.304 | -0.346 ± 0.269 |
| Week 52 | -0.180 ± 0.217 | -0.271 ± 0.354 | -0.404 ± 0.298 |
participants with Response Based on Rotterdam Criteria at Weeks 12 and 52 Rotterdam Published PBC Response Criteria by Visit (mITT Population) Rotterdam criteria: Early (normal total bilirubin and normal albumin), Moderately advanced (either abnormal albumin or abnormal total bilirubin), and Advanced (both abnormal albumin and abnormal total bilirubin). From Early stage to Moderate Stage and to Advanced Stage, it becomes worse and worse in abnormality.
| participants | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Early Stage,12 Weeks | 11 | 38 | 40 |
| Early Stage, 52 weeks | 10 | 36 | 42 |
| Moderately advanced at 12 Weeks: Either abnormal Albumin or abnormal Total Bilirubin | 0 | 7 | 9 |
| Moderately advanced: 52 Weeks, Either abnormal Albumin or abnormal Total Bilirubin | 0 | 3 | 5 |
| Advanced: 12 Weeks, Both abnormal Albumin and abnormal Total Bilirubin | 0 | 1 | 0 |
| Advanced: 52 Weeks Both abnormal Albumin and abnormal Total Bilirubin | 0 | 3 | 1 |
Percentage of participants with Response Defined by Composite Endpoint (ALP\< 1.67 \* Upper Limit of Normal \[ULN\] at Endpoint, Total Bilirubin \[BIL\] within Normal Limits at Endpoint, and Greater Than Equal To \[≥\] 15% ALP Reduction) from Baseline to Week 12 and Week 52 The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
| percentage of subjects | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Week 12 | 45.5 | 48.9 | 66.7 |
| Week 52 | 63.6 | 53.3 | 67.3 |
Percent change in ALP from baseline to Weeks 12 and 52 The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
| percentage Change | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) |
|---|---|---|---|
| Relative Change at Week 12 | -22.56 ± 13.92 | -34.49 ± 20.62 | -43.20 ± 12.39 |
| Relative Change at Week 52 | -32.72 ± 22.48 | -40.09 ± 24.23 | -44.19 ± 15.52 |
Collected over Up to Week 56. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MBX-8025 2 mg | 0/11 (0%) | 1/11 (9.1%) | 11/11 (100%) |
| MBX-8025 5 mg | 0/53 (0%) | 8/53 (15.1%) | 45/53 (84.9%) |
| MBX-8025 10 mg | 0/55 (0%) | 5/55 (9.1%) | 47/55 (85.5%) |
| Event | MBX-8025 2 mg | MBX-8025 5 mg | MBX-8025 10 mg |
|---|---|---|---|
| Rib fractureInjury, poisoning and procedural complications | 1/11 | 0/53 | 0/55 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/11 | 1/53 | 0/55 |
| Atrial fibrillationCardiac disorders | 0/11 | 1/53 | 0/55 |
| Abdominal pain upperGastrointestinal disorders | 0/11 | 1/53 | 0/55 |
| PneumoniaInfections and infestations | 0/11 | 1/53 | 1/55 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/11 | 1/53 | 0/55 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/11 | 1/53 | 0/55 |
| Procedural painInjury, poisoning and procedural complications | 0/11 | 1/53 | 0/55 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/11 | 1/53 | 0/55 |
| SyncopeNervous system disorders | 0/11 | 1/53 | 1/55 |
| Event | MBX-8025 2 mg | MBX-8025 5 mg | MBX-8025 10 mg |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 6/11 | 11/53 | 12/55 |
| DiarrhoeaGastrointestinal disorders | 4/11 | 7/53 | 9/55 |
| NauseaGastrointestinal disorders | 4/11 | 9/53 | 6/55 |
| NasopharyngitisInfections and infestations | 4/11 | 5/53 | 6/55 |
| Abdominal painGastrointestinal disorders | 3/11 | 3/53 | 3/55 |
| Abdominal pain upperGastrointestinal disorders | 3/11 | 7/53 | 5/55 |
| DyspepsiaGastrointestinal disorders | 3/11 | 2/53 | 1/55 |
| VomitingGastrointestinal disorders | 3/11 | 4/53 | 5/55 |
| FatigueGeneral disorders | 3/11 | 9/53 | 6/55 |
| Back painMusculoskeletal and connective tissue disorders | 3/11 | 5/53 | 3/55 |
18 to 75 years of age (inclusive)
| Age, Categorical(Participants) | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 41 | 41 | 90 |
| >=65 years | 3 | 12 | 14 | 29 |
| Age, Continuous(years) | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) | Total |
|---|---|---|---|---|
| Mean | 55.2 ± 9.6 | 57.5 ± 8.1 | 57.4 ± 9.7 | 56.4 ± 9.6 |
| Sex: Female, Male(Participants) | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) | Total |
|---|---|---|---|---|
| Female | 11 | 51 | 50 | 112 |
| Male | 0 | 2 | 5 | 7 |
| Race/Ethnicity, Customized(Subjects) | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) | Total |
|---|---|---|---|---|
| White | 10 | 50 | 49 | 109 |
| Black or African-American | 0 | 1 | 3 | 4 |
| Asian | 0 | 2 | 1 | 3 |
| American Indian or Alaska native | 0 | 0 | 1 | 1 |
| Other | 1 | 0 | 0 | 1 |
| Multiple | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | MBX-8025 (2 mg) | MBX-8025 (5 mg) | MBX-8025 (10 mg) | Total |
|---|---|---|---|---|
| Canada | 0 | 5 | 1 | 6 |
| United States | 0 | 39 | 43 | 82 |
| United Kingdom | 11 | 5 | 4 | 20 |
| Germany | 0 | 4 | 7 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2016 to primary completion in Sep 2018, 21 months.
Results were first posted in Jul 2022, 3 years 10 months after primary completion.
Of 21 phase 2 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 21 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Seladelpar